AU2003225253B2 - Drugs for mitigating taxane-induced neurotoxicity - Google Patents
Drugs for mitigating taxane-induced neurotoxicity Download PDFInfo
- Publication number
- AU2003225253B2 AU2003225253B2 AU2003225253A AU2003225253A AU2003225253B2 AU 2003225253 B2 AU2003225253 B2 AU 2003225253B2 AU 2003225253 A AU2003225253 A AU 2003225253A AU 2003225253 A AU2003225253 A AU 2003225253A AU 2003225253 B2 AU2003225253 B2 AU 2003225253B2
- Authority
- AU
- Australia
- Prior art keywords
- taxane
- antineoplastic agent
- drug
- taxane antineoplastic
- medication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940123237 Taxane Drugs 0.000 title claims abstract description 243
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title claims abstract description 237
- 229940079593 drug Drugs 0.000 title claims abstract description 198
- 239000003814 drug Substances 0.000 title claims abstract description 193
- 230000000116 mitigating effect Effects 0.000 title claims abstract description 40
- 206010029350 Neurotoxicity Diseases 0.000 title description 37
- 206010044221 Toxic encephalopathy Diseases 0.000 title description 37
- 231100000228 neurotoxicity Toxicity 0.000 title description 37
- 230000007135 neurotoxicity Effects 0.000 title description 37
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 225
- 229940034982 antineoplastic agent Drugs 0.000 claims abstract description 188
- 238000011282 treatment Methods 0.000 claims abstract description 90
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 46
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 36
- 230000003405 preventing effect Effects 0.000 claims abstract description 19
- 230000002411 adverse Effects 0.000 claims abstract description 8
- BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 claims description 83
- 229960004316 cisplatin Drugs 0.000 claims description 42
- 210000000578 peripheral nerve Anatomy 0.000 claims description 41
- 229930012538 Paclitaxel Natural products 0.000 claims description 39
- 229960001592 paclitaxel Drugs 0.000 claims description 39
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 39
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 32
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 27
- 238000002560 therapeutic procedure Methods 0.000 claims description 27
- 150000003057 platinum Chemical class 0.000 claims description 26
- 238000002651 drug therapy Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 238000004904 shortening Methods 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 12
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 11
- 229960003668 docetaxel Drugs 0.000 claims description 11
- 238000001990 intravenous administration Methods 0.000 claims description 10
- 229960004562 carboplatin Drugs 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 abstract description 31
- 206010028980 Neoplasm Diseases 0.000 abstract description 11
- 201000011510 cancer Diseases 0.000 abstract description 11
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 208000035475 disorder Diseases 0.000 description 31
- 230000036571 hydration Effects 0.000 description 19
- 238000006703 hydration reaction Methods 0.000 description 19
- 230000001988 toxicity Effects 0.000 description 19
- 231100000419 toxicity Toxicity 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 208000033808 peripheral neuropathy Diseases 0.000 description 16
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 13
- 238000011269 treatment regimen Methods 0.000 description 11
- 239000004615 ingredient Substances 0.000 description 9
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 208000035824 paresthesia Diseases 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 7
- 230000001934 delay Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 231100000862 numbness Toxicity 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 208000019430 Motor disease Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 108091006629 SLC13A2 Proteins 0.000 description 4
- 208000020764 Sensation disease Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000012910 preclinical development Methods 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000012829 chemotherapy agent Substances 0.000 description 3
- 230000007012 clinical effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- CETBSQOFQKLHHZ-UHFFFAOYSA-N Diethyl disulfide Chemical compound CCSSCC CETBSQOFQKLHHZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010029155 Nephropathy toxic Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 229940124444 chemoprotective agent Drugs 0.000 description 2
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007694 nephrotoxicity Effects 0.000 description 2
- 231100000417 nephrotoxicity Toxicity 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 206010056342 Pulmonary mass Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010071732 Retroperitoneal mass Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001767 chemoprotection Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- 229950009278 dimesna Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 201000010255 female reproductive organ cancer Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- SDNJNDFHCODQDQ-UHFFFAOYSA-N n-(2-ethylphenyl)-2-[[2-[(2-ethylphenyl)carbamoyl]phenyl]disulfanyl]benzamide Chemical compound CCC1=CC=CC=C1NC(=O)C1=CC=CC=C1SSC1=CC=CC=C1C(=O)NC1=CC=CC=C1CC SDNJNDFHCODQDQ-UHFFFAOYSA-N 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229940108949 paclitaxel injection Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940090016 tegretol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/135,975 US8710095B2 (en) | 2002-04-30 | 2002-04-30 | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US10/135,975 | 2002-04-30 | ||
| PCT/US2003/013518 WO2003092675A1 (en) | 2002-04-30 | 2003-04-29 | Drugs for mitigating taxane-induced neurotoxicity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003225253A1 AU2003225253A1 (en) | 2003-11-17 |
| AU2003225253B2 true AU2003225253B2 (en) | 2008-09-04 |
Family
ID=29249584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003225253A Ceased AU2003225253B2 (en) | 2002-04-30 | 2003-04-29 | Drugs for mitigating taxane-induced neurotoxicity |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8710095B2 (enExample) |
| EP (1) | EP1503748B1 (enExample) |
| JP (2) | JP5416327B2 (enExample) |
| AT (1) | ATE554753T1 (enExample) |
| AU (1) | AU2003225253B2 (enExample) |
| CA (1) | CA2483857A1 (enExample) |
| ES (1) | ES2381968T3 (enExample) |
| WO (1) | WO2003092675A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US20090111735A1 (en) * | 2004-05-12 | 2009-04-30 | Bionumerik Pharmaceuticals, Inc. | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| WO2007070599A2 (en) * | 2005-12-13 | 2007-06-21 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| WO2007109184A2 (en) * | 2006-03-16 | 2007-09-27 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
| EP2191836B1 (en) * | 2007-08-31 | 2012-05-23 | Kyushu University, National University Corporation | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent |
| JP5696266B2 (ja) | 2007-11-20 | 2015-04-08 | ランケナー インスティテュート フォー メディカル リサーチ | ジスルフィド化学療法剤およびその使用方法 |
| WO2009113984A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| US9320760B2 (en) * | 2008-03-14 | 2016-04-26 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| EP2249826B1 (en) * | 2008-03-14 | 2016-09-07 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| EP2249825B1 (en) * | 2008-03-14 | 2015-10-07 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| US20090232906A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| NZ601635A (en) | 2010-01-27 | 2013-06-28 | Takeda Pharmaceutical | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent |
| US11471431B2 (en) * | 2010-09-16 | 2022-10-18 | Lantern Pharma Inc. | Increasing cancer patient survival time by administration of dithio-containing compounds |
| EP3068411B1 (en) * | 2013-11-15 | 2020-03-18 | Oncolytics Biotech Inc. | Oncolytic viruses and increased cancer treatment regimens |
| AU2017384134B2 (en) * | 2016-12-19 | 2022-03-24 | Merck Patent Gmbh | Combination of a protein kinase inhibitor and an additional chemotherapeutic agent |
| WO2018194976A1 (en) * | 2017-04-17 | 2018-10-25 | Indiana University Research And Technology Corporation | Prevention and reversal of inflammation induced dna damage |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US6025488A (en) * | 1994-11-14 | 2000-02-15 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3140093A (en) * | 1991-11-22 | 1993-06-15 | University Of Mississippi, The | Synthesis and optical resolution of the taxol side chain and related compounds |
| FR2722987B1 (fr) * | 1994-07-29 | 1997-05-16 | Synthelabo | Utilisation de l'eliprodil et de ses enantiomeres pour la preparation de medicaments utiles dans la prevention des neuropathiesinduites par des agentsanticancereux |
| DE19617802A1 (de) * | 1996-05-03 | 1997-11-06 | Basf Ag | Verfahren zur heterogen katalysierten Herstellung von Hydroxyalkyl-substituierten Aminoalkinen |
| US6037336A (en) * | 1996-09-23 | 2000-03-14 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
| CA2263166C (en) | 1996-09-23 | 2006-12-12 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
| ES2163197T3 (es) | 1996-10-01 | 2002-01-16 | Bionumerik Pharmaceuticals Inc | Procedimiento para producir ditiobis-alcanosulfonatos y fosfonatos. |
| US6160167A (en) | 1998-04-21 | 2000-12-12 | Bionumerik Pharmaceuticals, Inc. | Mercaptans and disulfides |
| US6177411B1 (en) | 1999-02-09 | 2001-01-23 | Bionumerik Pharmaceuticals, Inc. | Method for treating heavy metal poisoning |
| US6172119B1 (en) | 1999-02-09 | 2001-01-09 | Bionumerik Pharmaceuticals, Inc. | Method of treating acute renal failure |
| US6197831B1 (en) | 1999-02-09 | 2001-03-06 | Bionumerik Pharmaceuticals, Inc. | Method of treating septic shock |
| US5998479A (en) | 1999-02-09 | 1999-12-07 | Bionumerik Pharmaceuticals, Inc. | Method of treating adult respiratory syndrome |
| US6075053A (en) | 1999-02-09 | 2000-06-13 | Bionumerik Pharmaceuticals, Inc. | Method of reducing or reversing neuropathy |
| US6034126A (en) | 1999-05-24 | 2000-03-07 | Bionumerik Pharmaceuticals, Inc. | Method for treating glycol poisoning |
| US6077838A (en) | 1999-06-08 | 2000-06-20 | Bionumerik Pharmaceuticals, Inc. | Method of treating hangover |
| US6143796A (en) | 1999-09-02 | 2000-11-07 | Bionumerik Pharmaceuticals, Inc. | Method for reducing development of free radical induced malignancies |
| US6468993B1 (en) | 1999-10-04 | 2002-10-22 | Bionumerik Pharmaceuticals, Inc. | Method for reducing development of osteoporosis |
| US6031006A (en) | 1999-10-21 | 2000-02-29 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic nephropathy |
| US6251881B1 (en) | 1999-10-21 | 2001-06-26 | Frederick H. Hausheer | Method of treating diabetic angiopathy |
| US6043274A (en) | 1999-10-21 | 2000-03-28 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic cardiomyopathy |
| US6100247A (en) | 1999-10-21 | 2000-08-08 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic neuropathy |
| US6274622B1 (en) | 1999-10-27 | 2001-08-14 | Frederick H. Hausheer | Method of treating diabetic ophthalmopathy |
| US6525037B1 (en) | 2000-02-25 | 2003-02-25 | Bionumerik Pharmaceuticals, Inc. | Method of treating atherosclerosis and complications resulting therefrom |
| AU2000239101A1 (en) * | 2000-03-22 | 2001-10-03 | Neopharm, Inc. | A method of administering liposomal encapsulated taxane |
| US6245815B1 (en) | 2000-04-15 | 2001-06-12 | Bionumerik Pharmaceuticals, Inc. | Method of treating alcoholism and complications resulting therefrom |
| US6468963B1 (en) | 2000-05-01 | 2002-10-22 | Bionumerik Pharmaceuticals, Inc. | Methods and formulations for reducing toxicity associated with diabetes treatments |
| FR2811987A1 (fr) | 2000-07-18 | 2002-01-25 | Expansia Sa | Procede de preparation du 2,2'-dithiobis(ethanesulfonate) de disodium |
| US6225295B1 (en) | 2000-09-27 | 2001-05-01 | Frederick H. Hausheer | Method of treating acetaminophen overdose |
| US6291441B1 (en) | 2000-09-27 | 2001-09-18 | Frederick H. Hausheer | Method of treating inflammatory bowel disorders |
| US6255355B1 (en) | 2001-01-06 | 2001-07-03 | Seetharamulu Peddaiahgari | Method of inhibiting angiogenesis |
| JP2004523518A (ja) | 2001-01-19 | 2004-08-05 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | より効能が大きく副作用の少ない癌治療方法 |
| US6352979B1 (en) | 2001-08-20 | 2002-03-05 | Lucinda Lizcano | Method of treating snakebite and complications resulting therefrom |
| US7176192B2 (en) | 2001-10-26 | 2007-02-13 | Bionumerik Pharmaceuticals, Inc. | Method for treating patients for radiation exposure |
| US6596320B1 (en) * | 2002-01-11 | 2003-07-22 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer having greater efficacy and reduced adverse effects |
| US6504049B1 (en) | 2002-04-30 | 2003-01-07 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing pharmaceutically active disulfide salts |
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| US20040014730A1 (en) | 2002-07-10 | 2004-01-22 | Frederick Hausheer | Formulations and methods of reducing toxicity of anti-infective agents |
| EP1583540A4 (en) | 2002-12-21 | 2006-07-26 | Bionumerik Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF TOXIC CHEMICALS EMITTED PATIENTS |
| US20040152774A1 (en) | 2003-02-04 | 2004-08-05 | Hausheer Frederick H. | Method of protecing against tissue extra vasation injury |
| WO2005058005A2 (en) | 2003-12-17 | 2005-06-30 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing disulfides |
-
2002
- 2002-04-30 US US10/135,975 patent/US8710095B2/en not_active Expired - Fee Related
-
2003
- 2003-04-29 ES ES03721972T patent/ES2381968T3/es not_active Expired - Lifetime
- 2003-04-29 AU AU2003225253A patent/AU2003225253B2/en not_active Ceased
- 2003-04-29 JP JP2004500859A patent/JP5416327B2/ja not_active Expired - Fee Related
- 2003-04-29 AT AT03721972T patent/ATE554753T1/de active
- 2003-04-29 CA CA002483857A patent/CA2483857A1/en not_active Abandoned
- 2003-04-29 WO PCT/US2003/013518 patent/WO2003092675A1/en not_active Ceased
- 2003-04-29 EP EP03721972A patent/EP1503748B1/en not_active Expired - Lifetime
-
2011
- 2011-04-13 JP JP2011089619A patent/JP2011140521A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| US5866169A (en) * | 1994-11-14 | 1999-02-02 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of use of 2,2'-dithio-bis-ethane sulfonate |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US6025488A (en) * | 1994-11-14 | 2000-02-15 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1503748B1 (en) | 2012-04-25 |
| US8710095B2 (en) | 2014-04-29 |
| WO2003092675A1 (en) | 2003-11-13 |
| JP2011140521A (ja) | 2011-07-21 |
| CA2483857A1 (en) | 2003-11-13 |
| EP1503748A1 (en) | 2005-02-09 |
| ATE554753T1 (de) | 2012-05-15 |
| AU2003225253A1 (en) | 2003-11-17 |
| JP5416327B2 (ja) | 2014-02-12 |
| US20030203960A1 (en) | 2003-10-30 |
| JP2005525409A (ja) | 2005-08-25 |
| EP1503748A4 (en) | 2009-10-21 |
| ES2381968T3 (es) | 2012-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003225253B2 (en) | Drugs for mitigating taxane-induced neurotoxicity | |
| AU2014251087B2 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| CN100411628C (zh) | 空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用 | |
| NZ510504A (en) | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin | |
| JP2005525409A5 (enExample) | ||
| US4609647A (en) | Cytidyl diphosphocholine-drug composition and process | |
| KR20020060226A (ko) | 배합 화학요법 | |
| MXPA04006822A (es) | Combinaciones que comprenden epotilonas y anti-metabolitos. | |
| JP2009292837A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| EP1273296B1 (en) | Combination of acetyldinaline and docetaxel | |
| EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| US20110118297A1 (en) | Tivozanib and Temsirolimus in Combination | |
| AU2002251763A1 (en) | Method for treating cancer | |
| US20040086536A1 (en) | Therapeutic agents and treatment kits for hypertrophic pyloric stenosis | |
| CN119816307A (zh) | 包含flt3抑制剂的癌症组合疗法 | |
| US20030134893A1 (en) | Combination chemotherapy | |
| MX2011006253A (es) | Combinacion antitumoral que asocia ave8062 y docetaxel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |